Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | HTR7 | P34969 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5069507 | 0.99 | TSHR (0.58) | TSHRPOLBSMN1; SMN2ALDH1A1RAB9A | |
| Bromide SCHEMBL5974838 | 0.95 | ALDH1A1 (0.53) | TSHRPOLBSMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL5141230 | 0.95 | ALDH1A1 (0.55) | TSHRPOLBSMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL5069508 | 0.80 | MAPT (0.52) | POLBSMN1; SMN2ALDH1A1RAB9AMEN1 | |
| Bromide SCHEMBL3846461 | 0.79 | MAPT (0.51) | POLBSMN1; SMN2ALDH1A1RAB9AMEN1 | |
| SCHEMBL12781882 | 0.76 | TSHR (0.73) | TSHRPOLBSMN1; SMN2ALDH1A1RAB9A | |
| Hydrochloric Acid SCHEMBL6772223 | 0.76 | LMNA (0.48) | TSHRPOLBSMN1; SMN2ALDH1A1RAB9A | |
| Hydrochloric Acid SCHEMBL5071117 | 0.76 | LMNA (0.48) | TSHRPOLBSMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL27571290 | 0.75 | L3MBTL1 (0.73) | TSHRPOLBSMN1; SMN2ALDH1A1RAB9A | |
| Hydrochloric Acid SCHEMBL3845513 | 0.75 | SMN1; SMN2 (0.54) | POLBSMN1; SMN2ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020160992-A1 | Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium salts | WAGLE DILIP R (US) | 2002-10-31 | — | — | US | claimed |
| EP-2085086-A2 | Method for treating congestive heart failure or diabetic nephropathy | Synvista Therapeutics, Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20090124674-A1 | Method for treating congestive heart failure | SYNVISTA THERAPEUTICS, INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124673-A1 | Method for treating diabetic nephropathy | SYNVISTA THERAPEUTICS , INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-7432254-B2 | Method for treating glaucoma IC | SYNVISTA THERAPEUTICS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7384625-B2 | Method and composition for rejuvenating hair, nails, tissues, cells and organs by ex-vivo or immersive treatment | FARINGTON PHARMACEUTICALS, LLC (US) | 2008-06-10 | — | — | US | disclosed |
| EP-1128830-B1 | REVERSING ADVANCED GLYCOSYLATION CROSS-LINKS USING HETEROCYCLIC-SUBSTITUTED THIAZOLIUM SALTS | SYNVISTA THERAPEUTICS INC (US) | 2008-03-12 | — | — | EP | disclosed |
| EP-1353669-B1 | METHOD FOR TREATING GLAUCOMA | ALTEON INC (US) | 2007-08-15 | — | — | EP | disclosed |
| US-7166625-B2 | Method for treating fibrotic diseases and other indications | ALTEON, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| EP-1305024-A4 | METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IC | ALTEON INC (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20020160993-A1 | Method for treating glaucoma IC | SYNVISTA THERAPEUTICS, INC. | 2002-10-31 | — | — | US | disclosed |
| US-20020160992-A1 | Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium salts | WAGLE DILIP R (US) | 2002-10-31 | — | — | US | disclosed |
| WO-2002056836-A2 | METHOD AND COMPOSITION FOR REJUVENATING HAIR, NAILS, TISSUES, CELLS AND ORGANS BY EX-VIVO OR IMMERSIVE TREATMENT | FARRINGTON PHARMACEUTICALS, LLC (US) | 2002-07-25 | — | — | WO | disclosed |
| WO-2002053158-A1 | METHOD FOR TREATING GLAUCOMA IB | ALTEON, INC. (US) | 2002-07-11 | — | — | WO | disclosed |
| US-20020068729-A1 | Method for treating fibrotic diseases or other indications IC | ALTEON, INC. | 2002-06-06 | — | — | US | disclosed |
| WO-2002007725-A1 | METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IC | ALTEON, INC. (US) | 2002-01-31 | — | — | WO | disclosed |
| US-6319934-B1 | TREATING STIFFENING OF BLOOD VASCULATURE, ATHEROSCLEROSIS, RETINOPATHY, CATARACTS, PERIPHERAL NEUROPATHY OR OSTEOARTHRITIS IN AN ANIMAL | ALTEON, INC. | 2001-11-20 | — | — | US | disclosed |
| EP-1128830-A1 | REVERSING ADVANCED GLYCOSYLATION CROSS-LINKS USING HETEROCYCLIC-SUBSTITUTED THIAZOLIUM SALTS | Alteon, Inc. (US) | 2001-09-05 | — | — | EP | disclosed |
| US-6121300-A | IN A TOPICAL COSMETIC AS SKIN ELASTICITY IMPROVER OR WRINKLE REDUCER; COMPOUNDS SUCH AS 3-(2-(3-PHENYL-5-ISOXAZOLYL)-2-OXOETHYL)-THIAZOLIUM; ADMINSISTERING TO TREAT CATARACTS, PROTEIN AGING AND DIABETES | SYNVISTA THERAPEUTICS, INC. | 2000-09-19 | — | — | US | disclosed |
| WO-2000027395-A1 | REVERSING ADVANCED GLYCOSYLATION CROSS-LINKS USING HETEROCYCLIC-SUBSTITUTED THIAZOLIUM SALTS | ALTEON, INC. (US) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020160993-A1 | Method for treating glaucoma IC | CHAT, MYOC, GAP43 | TSHR 3214/4885POLB 3857/4885SMN1; SMN2 3940/4885 |
| US-20020068729-A1 | Method for treating fibrotic diseases or other indications IC | MMP1, COL1A1, COL2A1 | TSHR 3040/4885POLB 2130/4885SMN1; SMN2 549/4885 |
| US-20090124673-A1 | Method for treating diabetic nephropathy | REN, SLC5A2, SLC5A1 | TSHR 3825/4885POLB 3981/4885SMN1; SMN2 1693/4885 |
| US-20020160992-A1 | Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium salts | AGER, OGA, PTMS | TSHR 617/4885POLB 3696/4885SMN1; SMN2 1808/4885 |
| US-20090124674-A1 | Method for treating congestive heart failure | TNNI3, TNNT2, FABP3 | TSHR 3017/4885POLB 4353/4885SMN1; SMN2 2173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.